Search | Clinical Trials Finder

Conditions: Post-Operative Pain
Interventions: Sufentanil NanoTab PCA System/15 mcg, morphine IV PCA; Drug
Lead sponsor: Talphera, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 16
States / cities: Florence, Alabama • Montgomery, Alabama • Sheffield, Alabama + 13 more

Conditions: Management of Chronic Pain
Interventions: Hydromorphone Hydrochloride, Programmable Implantable pump; Drug · Device
Lead sponsor: Piramal Critical Care, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Nondependent Opioid Abuse, Episodic
Interventions: Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pain
Interventions: St. John's Wort, oxycodone, fentanyl; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 21 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Analgesic Drug Dependence, Sensory Deficit
Interventions: sensory testing (Heat, cold, and pressure), Promis Survey; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Traumatic Brain Injury
Interventions: Mnemonic strategy training (MST), Repeated exposure (XP), Subtracting Cues training; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 88 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Healthy, PK Drug-drug Interaction Study
Interventions: Hydrocodone Bitartrate, Hydrocodone Bitartrate + Doxapram Hydrochloride; Drug
Lead sponsor: Quivive Pharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Pruritus Caused by Drug
Interventions: Ondansetron 8mg; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Interstitial Cystitis, Chronic Pain, Pelvic Floor; Relaxation, Pelvic Floor Disorders
Interventions: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device, Botulinum Neurotoxin; Device · Drug
Lead sponsor: HillMed Inc.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Delirium, Lumbar Radiculopathy, Lumbar Osteoarthritis, Lumbar Spine Disc Degeneration
Interventions: Light sedation with propofol, Induction with propofol, Maintenance anesthetic using a volatile anesthetic, Muscle relaxant during maintenance anesthesia, Pain control with fentanyl, Bispectral Index (BIS) monitoring for depth of anesthesia, Spinal Anesthesia, Midazolam administered during spinal anesthesia, Cerebrospinal fluid collection, Administration of intrathecal morphine; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid Substitution Treatment
Interventions: Ketorolac, Opioids, Ice Packs, Tylenol, Motrin, Dilaudid Injectable Product, Percocet 5Mg-325Mg Tablet; Drug · Other
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obstructive Sleep Apnea, Tonsillitis
Interventions: Hydromorphone, Fentanyl; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 2 Years to 15 Years
Enrollment: 189 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Opioid-Related Disorders, Opioid Withdrawal
Interventions: Buprenorphine/naloxone, Morphine, Tramadol; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Abdomen, Acute, Other Acute Pain, Flank Pain, Back Pain, Musculoskeletal Pain
Interventions: Ketamine, Morphine; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 59 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acute Pain
Interventions: Morphine, Placebo; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Multiple Sclerosis, Myasthenia Gravis
Interventions: CC-97540, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more

Conditions: Postoperative Pain
Interventions: Gabapentin, TAP Block; Drug · Procedure
Lead sponsor: State University of New York - Downstate Medical Center; Other
Eligibility: 18 Years to 60 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Vertebral Compression Fracture, Facet Joint Pain
Interventions: Radiofrequency ablation of the medial branch nerves, Non-steroidal anti-inflammatory drugs, Bisphosphonates, Acetaminophen, Physical therapy, Opioids; Procedure · Drug · Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Davis, California

Conditions: Moderate-severe Pain
Interventions: ALO-02; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Lancaster, California • Los Angeles, California • Sacramento, California + 4 more

Conditions: Depression, Opioid Use, Chronic Pain, Anxiety
Interventions: Electronic medical recorded clinical decision support [EMR CDS], Stepped opioid collaborative care model [CCM]; Behavioral
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Pelvic Organ Prolapse (POP), Stress Urinary Incontinence (SUI), Postoperative Pain
Interventions: Suzetrigine, Opioid Analgesics (Tramadol or Oxycodone), Scheduled Acetaminophen and Ibuprofen; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain
Interventions: Fentanyl Nasal Spray, Hydromorphone PCA, Placebo Nasal Spray; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Sclerosis, Relapsing Forms
Interventions: MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, PLACEBO-IV-SC, MEDI-551 100 MG-IV, MEDI-551 300 MG-SC, MEDI-551 600 MG-IV; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 9
States / cities: Scottsdale, Arizona • Long Beach, California • Sacramento, California + 6 more

Conditions: Baseline Epidemiologic Assessment
Interventions: MorphaBond ER, Comparator Drug; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: Not listed
Enrollment: 17,566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Search by objective public record fields.

A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration

Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

Herb-Opioid Interactions

Quantitative Sensory Testing in Chronic Pain Patients Undergoing Opioid Treatment and Opioid Tapering

Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI)

Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension

Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section

A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management

Shaping Anesthetic Techniques to Reduce Post-operative Delirium

ICE-T Pain Regimen for Total Laparoscopic Hysterectomy

Hydromorphone vs Fentanyl in Children Undergoing Tonsillectomy Surgery

Comparison of Three Opioid Detoxification Treatment Regimens

Low Dose Ketamine (LDK) Versus Morphine for Acute Pain Control in the Emergency Department

Study to Examine Pain Relief With Supplemental Intrathecal Morphine in TKA Patients

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Combination of Preoperative Gabapentin and TAP Blocks in Decreasing Postoperative Pain

Radiofrequency Ablation: Treatment for Posterior Element Pain From Vertebral Compression Fractures

Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

Opioid Treatment and Recovery Through a Safe Pain Management Program

Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery

Fentanyl for Breakthrough Pain in the Emergency Department

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)